Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Up – Here’s Why

Ono Pharmaceutical Co. (OTCMKTS:OPHLF)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $15.00, but opened at $16.11. Ono Pharmaceutical shares last traded at $16.11, with a volume of 300 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Zacks Research downgraded shares of Ono Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 4th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Ono Pharmaceutical currently has an average rating of “Hold”.

Ono Pharmaceutical Stock Up 13.9%

The company has a quick ratio of 2.86, a current ratio of 3.28 and a debt-to-equity ratio of 0.08. The company has a market cap of $7.57 billion, a price-to-earnings ratio of 15.34 and a beta of 0.33. The stock has a fifty day moving average price of $14.89 and a two-hundred day moving average price of $14.60.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd. is a Japanese research-driven pharmaceutical company headquartered in Osaka. The company discovers, develops, manufactures and markets prescription medicines, with a focus on oncology, immunology, neurology and other specialty-care areas. Its activities include both internally developed products and collaborations with pharmaceutical and biotechnology companies worldwide.

Ono is best known internationally for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb and used to treat multiple types of cancer.